Follow-Up After HCV Cure in Patients with Stage 3 Fibrosis or Cirrhosis
All patients with stage 3 fibrosis or cirrhosis who achieve sustained virologic response (SVR) require lifelong hepatocellular carcinoma (HCC) surveillance with liver imaging ± alpha-fetoprotein (AFP) every 6 months, indefinitely 1.
Virologic Confirmation and Monitoring
- Confirm SVR at 12 weeks post-treatment with undetectable HCV RNA using a sensitive assay (lower limit of detection <12 IU/mL) 1
- Reconfirm SVR at 48 weeks post-treatment as routine practice 1
- No routine HCV RNA testing beyond 48 weeks is needed to evaluate for late relapse, as this occurs in <1% of patients 1
- Exception: Perform periodic HCV RNA testing only in patients with ongoing risk factors for reinfection (e.g., active injection drug use, high-risk sexual practices) 1
HCC Surveillance Protocol
The surveillance regimen is non-negotiable for advanced fibrosis patients:
- Ultrasound imaging every 6 months for life 1
- AFP measurement can be added to ultrasound but is optional 1
- Do not intensify screening frequency beyond twice yearly in the immediate post-SVR period 1
- Do not discontinue surveillance even if fibrosis markers improve, as HCC risk persists 1
The 2024 EASL position paper 2 reinforces this approach, and recent research confirms that 14.5-17.6% of cirrhotic patients develop HCC or decompensation within 5 years despite SVR 3. Post-SVR liver stiffness >19 kPa at 6 months increases HCC/decompensation risk 14.5-fold 4.
Variceal Screening and Monitoring
For patients with cirrhosis:
- Perform initial upper endoscopy to screen for esophagogastric varices, regardless of SVR status 1
- Repeat endoscopy at 2-3 years if no varices or only small varices were found initially 1
- Consider stopping endoscopic surveillance after a negative 2-3 year follow-up endoscopy if there are no risk factors for progressive cirrhosis (e.g., ongoing alcohol use, metabolic dysfunction) 1
Fibrosis Assessment Post-SVR
Non-invasive fibrosis monitoring can guide management but should not alter HCC surveillance:
- Consider transient elastography (FibroScan) or FIB-4/APRI scores on an individual basis to assess for fibrosis progression or regression 1
- The 2024 EASL guideline 2 notes that early post-SVR decreases in liver stiffness reflect reduced inflammation rather than true fibrosis regression, while long-term decreases likely represent actual fibrosis improvement
- A FIB-4 ≥3.25 after SVR identifies F3 patients at 12-fold higher HCC risk who particularly benefit from surveillance 5
- Liver stiffness ≤8.6 kPa at 1 year post-treatment has 88.9% negative predictive value for excluding advanced fibrosis 6
Critical caveat: Even if fibrosis markers improve dramatically, do not reduce HCC surveillance frequency 1. Research shows advanced fibrosis persists in most patients, and cirrhosis regression is limited and slow, occurring in only 47% of mild cirrhosis cases (F4A) over 6+ years 6.
Additional Monitoring
Counsel patients and monitor for:
- Hepatotoxic exposures: alcohol consumption, fatty liver disease, other hepatotoxins 1
- Evaluate elevated liver enzymes for alternative causes of liver injury 1
- Monitor for extrahepatic manifestations: The 2024 EASL paper 2 emphasizes guidance on managing extrahepatic HCV complications post-cure
Laboratory Trends Post-SVR
Expect improvements in:
- Albumin, liver enzymes, AFP, platelet count 3
- MELD, FIB-4, and APRI scores 3
- Liver stiffness measurements 3, 4
These improvements reflect reduced inflammation and potential fibrosis regression but do not eliminate the need for ongoing surveillance in patients who had advanced disease pre-treatment.